2014 Multiple Sclerosis Therapeutic Update

The Neurohospitalist

Volumn 4, Issue 2, 2014, Pages 63-65

  Cree, Bruce A C ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

clinical trials; progressive multiple sclerosis; randomized controlled trials; relapsing multiple sclerosis; therapeutics

Indexed keywords

EID: 84930212767     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874414525410     Document Type: Article

References (4)

1. Khan O Rieckmann P Boyko A Selmaj K Zivadinov R, GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013; 73(6):705–713.
2. Calabresi P Kieseier B Arnold D, et al. Clinical efficacy and safety of peginterferon β-1a in relapsing multiple sclerosis: data from the pivotal phase 3 ADVANCE study. Platform presentation at: 65th Annual Meeting of the American Academy of Neurology; March 16-23, 2013, San Diego, CA. Presentation S31.006.
3. Miller A Kappos L Comi G, et al. Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study Platform presentation at: 65th Annual Meeting of the American Academy of Neurology Annual Meeting 2013, March 16-23, 2013, San Diego, CA Presentation S01.004
4. Miller A Wolinsky J Kappos L, et al. TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome. Platform presentation at European Committee for Treatment and Research in Multiple Sclerosis; October 2-5, 2013, Copenhagen, Denmark. Presentation 99